title: [Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn disease. A survey of a Cochrane review].
authors.affiliation: Gastroenheden, Medicinsk Sektion, Herlev Hospital, DK-2730 Herlev. ohn@dadlnet.dk
authors.forename: Imad
authors.initials: I
authors.lastname: Al-Subeihe
authors.forename: Ole Haagen
authors.initials: OH
authors.lastname: Nielsen
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068582:Certolizumab Pegol; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D019317:Evidence-Based Medicine; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D000069285:Infliximab; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D011092:Polyethylene Glycols; D000069285:Infliximab; D000068879:Adalimumab; D000068582:Certolizumab Pegol